^(131)I难治性分化型甲状腺癌分子靶向治疗进展  

Progression on molecular-targeted therapy of radioiodine-refractory differentiated thyroid cancer

作　　者：刘敏[1] 陈立波[1] 

机构地区：[1]上海交通大学附属第六人民医院核医学科,上海200233

出　　处：《临床肿瘤学杂志》2015年第6期564-567,共4页Chinese Clinical Oncology

基　　金：国家自然科学基金面上项目(81271609);上海市科技启明星资助项目(12QH1401600)

摘　　要：放射性碘难治性分化型甲状腺癌患者因病灶摄碘功能不佳而无法从131I等传统治疗方法中获益。近年来,甲状腺癌分子病理学研究新成果为甲状腺癌的分子诊断和靶向治疗提供了新的契机,相关分子靶向治疗的临床试验和荟萃分析均取得了可喜的结果。本文从临床角度对放射性碘难治性分化型甲状腺癌分子靶向治疗的最新进展进行综述。There is no standard therapy for radioiodinerefractory differentiated thyroid cancer which do not respond to traditional therapies. Recently, a number of genetic alterations have been described in thyroid cancer, which provides an unprecedented opportunity for the identification of novel diagnostic and prognostic molecular markers as well as novel therapeutic targets. Novel moleculartargeted treatments hold great promise for radioiodinerefractory and surgically inoperable thyroid cancer as shown in the most recent clinical trials and metaanalysis. This review is to outline the modern thyroid cancer medicine from a clinical perspective, focusing on the latest advances in moleculartargeted therapy.

关 键 词：分化型甲状腺癌 放射性碘 分子靶向治疗 多激酶抑制剂 

分 类 号：R730.55[医药卫生—肿瘤] R736.1[医药卫生—临床医学]